CAM
Congress Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,363
| Closed | -$261K | – | 395 |
|
|
2025
Q1 | $261K | Buy |
+2,363
| New | +$261K | ﹤0.01% | 355 |
|
|
2024
Q3 | – | Sell |
-2,855
| Closed | -$393K | – | 371 |
|
|
2024
Q2 | $393K | Buy |
+2,855
| New | +$393K | ﹤0.01% | 346 |
|
|
2023
Q4 | – | Sell |
-4,229
| Closed | -$476K | – | 381 |
|
|
2023
Q3 | $476K | Sell |
4,229
-1,543
| -27% | -$174K | ﹤0.01% | 340 |
|
|
2023
Q2 | $544K | Sell |
5,772
-914,281
| -99% | -$86.2M | ﹤0.01% | 327 |
|
|
2023
Q1 | $93.1M | Buy |
920,053
+2,228
| +0.2% | +$226K | 0.87% | 53 |
|
|
2022
Q4 | $110M | Sell |
917,825
-176,352
| -16% | -$21.1M | 1.1% | 25 |
|
|
2022
Q3 | $116M | Buy |
1,094,177
+20,335
| +2% | +$2.16M | 1.25% | 17 |
|
|
2022
Q2 | $105M | Sell |
1,073,842
-37,006
| -3% | -$3.61M | 1% | 38 |
|
|
2022
Q1 | $104M | Buy |
1,110,848
+201,760
| +22% | +$18.9M | 0.89% | 53 |
|
|
2021
Q4 | $77.4M | Sell |
909,088
-102,684
| -10% | -$8.75M | 0.59% | 74 |
|
|
2021
Q3 | $97M | Buy |
1,011,772
+63,207
| +7% | +$6.06M | 0.76% | 72 |
|
|
2021
Q2 | $92.3M | Buy |
948,565
+46,731
| +5% | +$4.55M | 0.77% | 72 |
|
|
2021
Q1 | $87.7M | Buy |
901,834
+140,893
| +19% | +$13.7M | 0.79% | 68 |
|
|
2020
Q4 | $72.9M | Sell |
760,941
-6,709
| -0.9% | -$643K | 0.69% | 76 |
|
|
2020
Q3 | $73.8M | Buy |
+767,650
| New | +$73.8M | 0.8% | 69 |
|